Log in

NASDAQ:DRRX - DURECT Stock Price, Forecast & News

$1.99
-0.07 (-3.40 %)
(As of 12/6/2019 08:00 AM ET)
Today's Range
$1.96
Now: $1.99
$2.07
50-Day Range
$1.74
MA: $1.94
$2.19
52-Week Range
$0.46
Now: $1.99
$2.46
Volume565,800 shs
Average Volume784,259 shs
Market Capitalization$382.80 million
P/E RatioN/A
Dividend YieldN/A
Beta1.75
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products under the LACTEL brand. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DRRX
CUSIPN/A
Phone408-777-1417

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$18.56 million
Book Value$0.12 per share

Profitability

Net Income$-25,320,000.00
Net Margins-105.07%

Miscellaneous

Employees88
Market Cap$382.80 million
Next Earnings Date3/5/2020 (Estimated)
OptionableOptionable

Receive DRRX News and Ratings via Email

Sign-up to receive the latest news and ratings for DRRX and its competitors with MarketBeat's FREE daily newsletter.


DURECT (NASDAQ:DRRX) Frequently Asked Questions

What is DURECT's stock symbol?

DURECT trades on the NASDAQ under the ticker symbol "DRRX."

How were DURECT's earnings last quarter?

DURECT Co. (NASDAQ:DRRX) announced its quarterly earnings data on Monday, November, 4th. The specialty pharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.02 by $0.03. The specialty pharmaceutical company earned $10.76 million during the quarter, compared to analyst estimates of $7.78 million. DURECT had a negative return on equity of 119.34% and a negative net margin of 105.07%. View DURECT's Earnings History.

When is DURECT's next earnings date?

DURECT is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for DURECT.

What price target have analysts set for DRRX?

3 equities research analysts have issued 1 year target prices for DURECT's shares. Their forecasts range from $2.10 to $5.00. On average, they expect DURECT's stock price to reach $3.53 in the next year. This suggests a possible upside of 77.6% from the stock's current price. View Analyst Price Targets for DURECT.

What is the consensus analysts' recommendation for DURECT?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DURECT in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DURECT.

Has DURECT been receiving favorable news coverage?

News headlines about DRRX stock have been trending very positive this week, InfoTrie reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. DURECT earned a news sentiment score of 3.5 on InfoTrie's scale. They also assigned media headlines about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for DURECT.

Are investors shorting DURECT?

DURECT saw a increase in short interest in November. As of November 15th, there was short interest totalling 1,250,000 shares, an increase of 28.7% from the October 31st total of 971,000 shares. Based on an average daily volume of 790,200 shares, the short-interest ratio is currently 1.6 days. Approximately 0.8% of the shares of the stock are sold short. View DURECT's Current Options Chain.

Who are some of DURECT's key competitors?

What other stocks do shareholders of DURECT own?

Who are DURECT's key executives?

DURECT's management team includes the folowing people:
  • Dr. James E. Brown, Co-Founder, CEO, Pres & Director (Age 62)
  • Mr. Matthew J. Hogan, CFO & Sec. (Age 59)
  • Ms. Judy R. Joice, Sr. VP of Operations & Corp. Quality Assurance (Age 62)
  • Mr. Michael H. Arenberg, Chief Financial Officer (Age 49)
  • Dr. John W. Gibson B.S., M.S., VP of Birmingham Operations & Principal Scientist

Who are DURECT's major shareholders?

DURECT's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Ingalls & Snyder LLC (4.27%), Tocqueville Asset Management L.P. (0.59%), Millennium Management LLC (0.27%), Assenagon Asset Management S.A. (0.23%), California Public Employees Retirement System (0.16%) and Virtu Financial LLC (0.08%). Company insiders that own DURECT stock include First Eagle Investment Managem, James E Brown, Jon S Saxe and Michael Arenberg. View Institutional Ownership Trends for DURECT.

Which major investors are selling DURECT stock?

DRRX stock was sold by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC, Tower Research Capital LLC TRC and SG Americas Securities LLC. View Insider Buying and Selling for DURECT.

Which major investors are buying DURECT stock?

DRRX stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Millennium Management LLC, Virtu Financial LLC, California Public Employees Retirement System, Squarepoint Ops LLC, Tocqueville Asset Management L.P. and Commonwealth Equity Services LLC. Company insiders that have bought DURECT stock in the last two years include First Eagle Investment Managem, James E Brown, Jon S Saxe and Michael Arenberg. View Insider Buying and Selling for DURECT.

How do I buy shares of DURECT?

Shares of DRRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is DURECT's stock price today?

One share of DRRX stock can currently be purchased for approximately $1.99.

How big of a company is DURECT?

DURECT has a market capitalization of $382.80 million and generates $18.56 million in revenue each year. The specialty pharmaceutical company earns $-25,320,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. DURECT employs 88 workers across the globe.View Additional Information About DURECT.

What is DURECT's official website?

The official website for DURECT is http://www.durect.com/.

How can I contact DURECT?

DURECT's mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The specialty pharmaceutical company can be reached via phone at 408-777-1417.


MarketBeat Community Rating for DURECT (NASDAQ DRRX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  257 (Vote Outperform)
Underperform Votes:  175 (Vote Underperform)
Total Votes:  432
MarketBeat's community ratings are surveys of what our community members think about DURECT and other stocks. Vote "Outperform" if you believe DRRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DRRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/6/2019 by MarketBeat.com Staff

Featured Article: Total Return

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel